🚀 VC round data is live in beta, check it out!
Allurion Valuation Multiples
Discover revenue and EBITDA valuation multiples for Allurion and similar public comparables like Spineguard, Jana Medical Company, Renalytix, Arcoma and more.
Allurion Overview
About Allurion
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world’s first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Founded
2023
HQ
Employees
137
Website
Financials (LTM)
EV
$36M
Allurion Financials
Allurion reported last 12-month revenue of $15M.
Revenue (LTM)
Allurion P&L
In the most recent fiscal year, Allurion reported revenue of $15M and EBITDA of ($28M).
Allurion expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | $15M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $10M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 63% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($28M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (182%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (198%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($29M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (189%) | XXX | XXX | XXX |
| Net Debt | — | — | $23M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Allurion Stock Performance
Allurion has current market cap of $12M, and enterprise value of $36M.
Market Cap Evolution
Allurion's stock price is $0.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $36M | $12M | -31.6% | XXX | XXX | XXX | $-1.92 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAllurion Valuation Multiples
Allurion trades at 2.4x EV/Revenue multiple, and (1.3x) EV/EBITDA.
EV / Revenue (LTM)
Allurion Financial Valuation Multiples
As of April 18, 2026, Allurion has market cap of $12M and EV of $36M.
Equity research analysts estimate Allurion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Allurion has a P/E ratio of (0.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV (current) | $36M | XXX | $36M | XXX | XXX | XXX |
| EV/Revenue | 2.4x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (1.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.7x | XXX | XXX | XXX |
| P/E | — | XXX | (0.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Allurion Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Allurion Margins & Growth Rates
Allurion's revenue in the last 12 month grew by 19%.
Allurion's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Allurion Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (182%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 71% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 140% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 50% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 261% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Allurion Public Comps
See public comps and valuation multiples for other Medical Devices and Health Data & Analytics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Allurion | XXX | XXX | XXX | XXX | XXX | XXX |
| Spineguard | XXX | XXX | XXX | XXX | XXX | XXX |
| Jana Medical Company | XXX | XXX | XXX | XXX | XXX | XXX |
| Renalytix | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcoma | XXX | XXX | XXX | XXX | XXX | XXX |
| Lifecare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Allurion M&A Activity
Allurion acquired XXX companies to date.
Last acquisition by Allurion was on XXXXXXXX, XXXXX. Allurion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Allurion
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAllurion Investment Activity
Allurion invested in XXX companies to date.
Allurion made its latest investment on XXXXXXXX, XXXXX. Allurion invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Allurion
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Allurion
| When was Allurion founded? | Allurion was founded in 2023. |
| Where is Allurion headquartered? | Allurion is headquartered in United States. |
| How many employees does Allurion have? | As of today, Allurion has over 137 employees. |
| Who is the CEO of Allurion? | Allurion's CEO is Shantanu Gaur. |
| Is Allurion publicly listed? | Yes, Allurion is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of Allurion? | Allurion trades under ALUR ticker. |
| When did Allurion go public? | Allurion went public in 2023. |
| Who are competitors of Allurion? | Allurion main competitors are Spineguard, Jana Medical Company, Renalytix, Arcoma. |
| What is the current market cap of Allurion? | Allurion's current market cap is $12M. |
| What is the current revenue of Allurion? | Allurion's last 12 months revenue is $15M. |
| What is the current revenue growth of Allurion? | Allurion revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Allurion? | Current revenue multiple of Allurion is 2.4x. |
| Is Allurion profitable? | No, Allurion is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.